Epi One aims to take early cancer diagnosis to the next level by leveraging a novel epigenetic biomarker platform.
Epi One has raised $2.1M in total funding. The most recent round was Equity Crowdfunding. The last funding was announced in December 2024.
Epi One is headquartered in Brooklyn, United States.
Epi One aims to take early cancer diagnosis to the next level by leveraging a novel epigenetic biomarker platform.
Epi One is at the Equity Crowdfunding stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Epi One — Funding & Investors." VCBacked, December 5, 2024, https://www.vcbacked.co/company/epi-one. Accessed September 30, 2026.
VCBacked. (2024). Epi One — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/epi-one
{{cite web |title=Epi One — Funding & Investors |url=https://www.vcbacked.co/company/epi-one |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated